Streetbeat News

Analyst Ratings

SJM

JP Morgan analyst Ken Goldman maintains a Neutral rating on JM Smucker (NYSE:SJM) and lowers the price target from $158 to $153.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 1:53 pm

EXC

JP Morgan analyst Jeremy Tonet maintains an Overweight rating on Exelon (NASDAQ:EXC) but lowers the price target from $50 to $46.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 1:51 pm

ES

JP Morgan analyst Christopher Turnure maintains a Neutral rating on Eversource Energy (NYSE:ES) and lowers the price target from $87 to $78.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 1:51 pm

ED

JP Morgan analyst Jeremy Metz maintains an Underweight rating on Consolidated Edison (NYSE:ED) and lowers the price target from $89 to $80.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 1:49 pm

NFLX

Netflix shares are trading higher after JPMorgan and Wells Fargo analysts increased their price targets on the stock. The company has recently ramped up its crackdown on password sharing, which is expected to drive increased revenues.

Portfolio Pulse from Adam Eckert

June 07, 2023 | 1:49 pm

CIEN

JP Morgan analyst Samik Chatterjee maintains an Overweight rating on Ciena (NYSE:CIEN) but lowers the price target from $67 to $65.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 1:48 pm

BALL

JP Morgan analyst Jeffrey Zekauskas maintains a Neutral rating on Ball Corporation (NYSE: BALL) and lowers the price target from $61 to $57.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 1:48 pm

MOMO

Benchmark analyst Fawne Jiang maintains a Buy rating on Hello Gr (NASDAQ:MOMO) and raises the price target from $21 to $22.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 1:45 pm

IAS

Benchmark analyst Mark Zgutowicz initiates coverage on Integral Ad Science (NASDAQ:IAS) with a Hold rating.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 1:43 pm

TVTX

Piper Sandler analyst Nicole Gabreski assumes Travere Therapeutics (NASDAQ:TVTX) with a Neutral rating and announces a price target of $22.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 1:41 pm